High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group

The present retrospective analysis evaluated the efficacy and safety of the VTD (bortezomib, thalidomide, dexamethasone) regimen in 205 newly-diagnosed patients with multiple myeloma (MM) eligible for high dose therapy and autologous stem cell transplantation (HDT/ASCT) in routine clinical practice....

Descripción completa

Detalles Bibliográficos
Autores principales: Hus, Iwona, Mańko, Joanna, Jawniak, Dariusz, Jurczyszyn, Artur, Charliński, Grzegorz, Poniewierska-Jasak, Katarzyna, Usnarska-Zubkiewicz, Lidia, Sawicki, Mateusz, Druzd-Sitek, Agnieszka, Świderska, Alina, Kopińska, Anna, Grząśko, Norbert, Raźny, Małgorzata, Wędłowska, Aleksandra, Perzyński, Aleksander, Gałązka, Aleksandra, Dytfeld, Dominik, Kubicki, Tadeusz, Rodzaj, Marek, Waszczuk-Gajda, Anna, Drozd-Sokołowska, Joanna, Pogłódek, Bartłomiej, Pasternak, Anna, Długosz-Danecka, Monika, Szymczyk, Agnieszka, Dmoszyńska, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865789/
https://www.ncbi.nlm.nih.gov/pubmed/31788054
http://dx.doi.org/10.3892/ol.2019.10929

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6865789/
https://www.ncbi.nlm.nih.gov/pubmed/31788054
http://dx.doi.org/10.3892/ol.2019.10929

Ejemplares similares